ARGX
NASDAQargenx SE
Website
News25/Ratings12
News · 26 weeks36-71%
2025-10-262026-04-19
Mix1590d
- SEC Filings6(40%)
- Other5(33%)
- Earnings2(13%)
- Analyst1(7%)
- Leadership1(7%)
Latest news
25 items- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDPADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient populationADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx announces Annual General Meeting of Shareholders on May 6, 2026March 20, 2026 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting a
- SECSEC Form 20-F filed by argenx SE20-F - ARGENX SE (0001697862) (Filer)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- ANALYSTargenx upgraded by Deutsche BankDeutsche Bank upgraded argenx from Hold to Buy
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of PipelinePositive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who do not have detectable AChR-Ab – demonstrate VYVGART's efficacy and safety across subtypesNew biomarker analysis, real-world evidence and post-hoc insights highlight VYVGART's expanding treatment approach in CIDP March 6, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will present data for VYVGART® (IV: efgartigimod alfa-f
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative ("seronegative") gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported f
- PRargenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia GravisStudy met primary endpoint (p-value = 0.012)First registrational study to specifically evaluate a targeted treatment for patients living with ocular MG Results support planned Supplemental Biologics License Application (sBLA) submission to U.S. Food and Drug Administration (FDA) to expand label into oMG Regulated Information – Inside Information February 26, 2026, 6:30 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART® (efgartigimod alfa and hyaluronida
- PRargenx to Present at TD Cowen 46th Annual Healthcare ConferenceFebruary 23, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, Chief Operating Officer, will participate in a fireside chat at the TD Cowen 46th Annual Healthcare Conference on Monday, March 2 at 11:50 a.m. ET. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation. About argenx argenx is a global immunology company committed to improving the
- PRargenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026February 19, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, February 26, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its full year 2025 financial results and provide a fourth quarter business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium 32 800 50
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMGJanuary 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). The application has been granted a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026. "Patients living with seronegative gMG continue to face lim
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Highlights 2026 Strategic PrioritiesReported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end January 12, 2026, 7:00 a.m. CETAmsterdam, the Netherlands – argenx ((Euronext &, NASDA
- PRargenx to Present at 44th Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation. About argenx argenx is a global immunology company committed to improving the lives
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)
- PRargenx Announces Leadership Transition Marking Next Evolution of GrowthTim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and Executive Director and Tim Van Hauwermeiren, current Chief Executive Officer, will transition to non-Executive Director and Chairman of the Board of Directors. Tim will succeed Peter Verhaeghe, w
- ANALYSTargenx downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded argenx from Outperform to Neutral and set a new price target of $858.00
- SECSEC Form S-8 filed by argenx SES-8 - ARGENX SE (0001697862) (Filer)
- SECSEC Form 6-K filed by argenx SE6-K - ARGENX SE (0001697862) (Filer)